A key mechanism of tumor resistance to immune cells is mediated by expression of peptide-loaded HLA (human leukocyte antigen)-E in tumor cells, which suppresses NK and CD8 cell activity via ligation of the NK inhibitory receptor CD94/NKG2A. Here, KLRC1 is linked to neoplasm.